228 related articles for article (PubMed ID: 35612971)
21. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.
Chiba Y; Kagabu M; Osakabe M; Ito R; Sato S; Takatori E; Kaido Y; Nagasawa T; Shoji T; Yanagawa N; Baba T
Jpn J Clin Oncol; 2024 Apr; 54(4):424-433. PubMed ID: 38251744
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma.
Walker CA; Spirtos AN; Miller DS
Expert Rev Anticancer Ther; 2023 Apr; 23(4):361-368. PubMed ID: 36944439
[TBL] [Abstract][Full Text] [Related]
23. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Zammarrelli WA; Ma W; Espino K; Gordhandas S; Yeoshoua E; Ehmann S; Zhou Q; Iasonos A; Abu-Rustum NR; Aghajanian C; Green AK; Rubinstein MM; Makker V
Gynecol Oncol; 2023 Nov; 178():27-35. PubMed ID: 37748268
[TBL] [Abstract][Full Text] [Related]
24. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Fradet Y; Bellmunt J; Vaughn DJ; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Nam K; Frenkl TL; Perini RF; de Wit R; Bajorin DF
Ann Oncol; 2019 Jun; 30(6):970-976. PubMed ID: 31050707
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
[TBL] [Abstract][Full Text] [Related]
30. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Eskander RN; Sill MW; Beffa L; Moore RG; Hope JM; Musa FB; Mannel R; Shahin MS; Cantuaria GH; Girda E; Mathews C; Kavecansky J; Leath CA; Gien LT; Hinchcliff EM; Lele SB; Landrum LM; Backes F; O'Cearbhaill RE; Al Baghdadi T; Hill EK; Thaker PH; John VS; Welch S; Fader AN; Powell MA; Aghajanian C
N Engl J Med; 2023 Jun; 388(23):2159-2170. PubMed ID: 36972022
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
34. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
[TBL] [Abstract][Full Text] [Related]
35. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Kawazoe A; Fukuoka S; Nakamura Y; Kuboki Y; Wakabayashi M; Nomura S; Mikamoto Y; Shima H; Fujishiro N; Higuchi T; Sato A; Kuwata T; Shitara K
Lancet Oncol; 2020 Aug; 21(8):1057-1065. PubMed ID: 32589866
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
[TBL] [Abstract][Full Text] [Related]
37. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Colombo N; Lorusso D; Monk BJ; Slomovitz B; Hasegawa K; Nogueira-Rodrigues A; Zale M; Okpara CE; Barresi G; McKenzie J; Makker V
Oncologist; 2024 Jan; 29(1):25-35. PubMed ID: 37523661
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
[TBL] [Abstract][Full Text] [Related]
39. Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA.
Wada K; Zhang J; Lee I; Wang Y; Near A; Prabhu VS
Future Oncol; 2024 Feb; 20(5):257-267. PubMed ID: 37828843
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Makker V; Taylor MH; Aghajanian C; Cohn AL; Brose MS; Simone CD; Cao ZA; Suttner L; Loboda A; Cristescu R; Jelinic P; Orlowski R; Dutta L; Matsui J; Dutcus CE; Minoshima Y; Messing MJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
